COVID-19: Biological E, Providence Therapeutics partner to produce 1 billion doses of mRNA vaccine in India
India’s Biological E Ltd and Canadian biotech firm Providence Therapeutics Holdings Inc have entered into an agreement to manufacture the latter’s mRNA vaccine PTX-Covid-19-B in India.
According to a release from the city-based vaccine maker, Providence will provide the necessary technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses. Biological E will be responsible for all clinical development and regulatory activities for the mRNA vaccine in India and other jurisdictions licensed by it. It targets one billion dose production capacity in 2022.
“Providence will provide the necessary technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses, it said. The mRNA platform has emerged as the front runner in delivering the first vaccines for emergency use to combat the COVID-19 pandemic. Biological E is very pleased to be able to work with Providence on its promising mRNA vaccine candidate, Mahima Datla, Managing Director of Biological E said.
“We hope to provide India and other countries yet another option to ramp up their efforts towards achieving herd immunity against COVID-19,” she said. The initiative is an important commitment by a Canada- based company to help India and other nations vaccinate their citizens against COVID19, Brad Sorenson, CEO of Providence said. “Providence was founded to serve patients, and this commitment by Biological E allows us to achieve that essential goal,” Sorenson said.
Also Read: Speeding up vaccination also important for health of economy: CEA
Providence will export 30 million doses from existing North American capacity to Biological E and other end buyers, it said. Earlier, Biological E Ltd had said it entered into a collaboration with Janssen Pharmaceutica NV, part of pharma majorJohnson&Johnson, for creation and enhancement of production capabilities to manufacture the latter”s COVID-19 vaccine.
(with agency inputs)
Pingback: COVID impact: Flexible working key for attracting, retaining top talent, says survey
Pingback: Gowda says there is stabilised supply-demand balance of COVID treatment drugs
Pingback: Google seeks exemption from new IT rules, says we are not social media
Pingback: FICCI suggests graded approach to unlock economic activities
Pingback: Covid-19 Vaccine: Centre buys 30 crore doses from Hyderabad-based Biological-E in advance
Pingback: Kerala retains top spot in Niti Aayog's SDG Index, Bihar at the bottom
Pingback: Govt proposes making national permit fee payment online for goods vehicles
Pingback: Hiring activity improves sequentially in May: Report
Pingback: RBI keeps repo rate unchanged at 4 pc; cuts growth forecast to 9.5 pc
Pingback: World Environment Day 2021: India advances 20 PC ethanol-blending in petrol by 5 years to 2025